Source: Cristalia & reported by http://www.prnewswire.com/
SAO PAULO, June 6, 2016 /PRNewswire/ -- The National Agency of Health Oversight (ANVISA - Agencia Nacional de Vigilancia Sanitaria) has allowed Laboratorio Cristalia to register the first biological Active Pharmaceutical Ingredient (API) based on the biodiversity of Brazil. It is called Colagenase Cristalia, an enzyme used in the production of ointments for the treatment of wounds (enzymatic debridement), burns and necrotic tissue.
"The registration of the API Colagenase Cristalia is one of our greatest achievements. We invested in research, development and innovation to arrive at a first rate medication. This is the first biotechnological API from Brazilian biodiversity that will be produced here, and will provide the opportunity to export this active ingredient," noted Dr. Ogari Pacheco, President of the Board of Cristalia.
The Biotechnology Division of Cristalia, headed up by Marcos Alegria, started production of the enzyme from a strain discovered on a farm in Espirito Santo do Pinhal, in the interior of Sao Paulo state. The productive process was registered with the Council for the Management of Genetic Assets (CGEN - Conselho de Gestao do Patrimonio Genetico) and the strain was deposited with the Brazilian Collection of Microorganisms of the Environment and Industry (CBMAI – Colecao Brasileira de Microrganismos de Ambiente e Industria), a body at Unicamp selected by CGEN as the designated depository of Brazilian biological samples.
Read more: http://www.prnewswire.com/news-releases/cristalia-obtains-registration-for-first-biotechnological-pharmaceutical-ingredient-300280459.html